ST316, a β-catenin/BCL9 antagonist, demonstrated safety, target engagement, and early antitumor activity in advanced solid tumors.

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States and a top ...

Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock ...

Seth Wander, MD, PhD, discusses approved and upcoming targeted therapies for patients with ESR1-mutated breast cancer.